Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics shares have added about 96.1% since the beginning of the year versus the S&P 500's gain of 18.1%. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.69 on $15.84 million in revenues for the coming quarter and -$2.85 on $64.98 million in revenues for the current fiscal year. This biopharmaceutical company is expected to post quarterly earnings of $1.66 per share in its upcoming repo ...